{"": [128, 137, 0, 138, 1049, 0], "Introduction": [1050, 4888, 0], "DNA vaccine construction and production": [4912, 6862, 0], "S1 protein production and use": [6863, 7635, 0], "Western blot analysis": [7636, 8220, 0], "Pilot animal studies": [8243, 9631, 0], "Optimal vaccination design studies": [9632, 10245, 0], "Non-human primate (NHP) immunogenicity and protection study": [10246, 11313, 0], "Animal immunizations": [8221, 11313, 1], "Virus and cell line": [11314, 12544, 0], "ELISA": [12545, 13456, 0], "Neutralization antibody assays": [13457, 15622, 0], "ELISpot assay": [15623, 17213, 0], "Realtime-RT-PCR assay": [17214, 18312, 0], "Histopathological analysis": [18313, 18854, 0], "Statistical analyses": [18855, 19270, 0], "Materials and methods": [4889, 19270, 1], "Overall study design and S antigen selection": [19280, 23253, 0], "Immunogenicity of prime-boost vs. co-delivery of DNA and protein vaccines": [23254, 27805, 0], "Protection against SARS-CoV-2 challenge in a non-human primate model": [27806, 30984, 0], "Results": [19271, 30984, 1], "Discussion": [30985, 38821, 0]}